Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Terns Pharmaceuticals Inc (TERN)

Terns Pharmaceuticals Inc (TERN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 475,658
  • Shares Outstanding, K 84,939
  • Annual Sales, $ 0 K
  • Annual Income, $ -90,210 K
  • EBIT $ -100 M
  • EBITDA $ -104 M
  • 60-Month Beta -0.32
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.14

Options Overview Details

View History
  • Implied Volatility 71.26% ( -33.59%)
  • Historical Volatility 54.01%
  • IV Percentile 13%
  • IV Rank 15.46%
  • IV High 313.50% on 05/31/24
  • IV Low 26.95% on 10/08/24
  • Put/Call Vol Ratio 0.10
  • Today's Volume 56
  • Volume Avg (30-Day) 525
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 13,511
  • Open Int (30-Day) 11,791

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.30
  • Number of Estimates 4
  • High Estimate -0.27
  • Low Estimate -0.38
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -3.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.47 +4.57%
on 11/21/24
7.63 -25.03%
on 11/11/24
-1.52 (-20.99%)
since 10/21/24
3-Month
5.47 +4.57%
on 11/21/24
11.40 -49.82%
on 09/10/24
-2.16 (-27.41%)
since 08/21/24
52-Week
3.59 +59.33%
on 11/24/23
11.40 -49.82%
on 09/10/24
+1.95 (+51.72%)
since 11/21/23

Most Recent Stories

More News
Terns Pharmaceuticals Appoints Heather Turner to Board of Directors, Ann E. Taylor Steps Down

Terns Pharmaceuticals appoints Heather Turner to its Board of Directors, succeeding Ann Taylor after her three-year tenure.Quiver AI SummaryTerns Pharmaceuticals, Inc. has appointed Heather Turner, J.D.,...

TERN : 5.71 (+1.96%)
Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

TERN : 5.71 (+1.96%)
Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates

TERN : 5.71 (+1.96%)
Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences

TERN : 5.71 (+1.96%)
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

TERN : 5.71 (+1.96%)
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments

Terns has a modest market cap of less than $800 million, and its possible upside could be massive.

LLY : 751.16 (-0.30%)
GS : 598.79 (+2.90%)
TERN : 5.71 (+1.96%)
VKTX : 52.34 (+1.57%)
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.

Terns Pharmaceuticals just proved that it's competitive in the weight loss field.

VKTX : 52.34 (+1.57%)
TERN : 5.71 (+1.96%)
Should You Invest in This Under-the-Radar Weight Loss Stock?

Getting in on the ground floor sounds like a great idea, but not if the building ends up crumbling.

LLY : 751.16 (-0.30%)
TERN : 5.71 (+1.96%)
1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More

This biotech's data suggests that it could have an advantage in its target market.

TERN : 5.71 (+1.96%)
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?

At least one of the pair has a credible shot at finding a home in the market.

LLY : 751.16 (-0.30%)
ALT : 8.62 (+7.08%)
TERN : 5.71 (+1.96%)

Business Summary

Terns Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in development of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and other chronic liver diseases. Terns Pharmaceuticals Inc. is based in FOSTER CITY,...

See More

Key Turning Points

3rd Resistance Point 6.19
2nd Resistance Point 6.05
1st Resistance Point 5.83
Last Price 5.71
1st Support Level 5.47
2nd Support Level 5.33
3rd Support Level 5.11

See More

52-Week High 11.40
Fibonacci 61.8% 8.42
Fibonacci 50% 7.49
Fibonacci 38.2% 6.57
Last Price 5.71
52-Week Low 3.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar